SCHEMBL5537324

SCHEMBL5537324

CN(C(=O)Oc1ccccc1)C1CO1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
ATM Q13315 1/20 0.47
ALDH1A1 P00352 5/20 0.45
KMT2A Q03164 4/20 0.45
PKM P14618 1/20 0.45
RAB9A P51151 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.42
NPC1 O15118 2/20 0.42
MEN1 O00255 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
NPY5R Q15761 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.39
GFER P55789 1/20 0.39
LMNA P02545 2/20 0.38
BCHE P06276 1/20 0.37
GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9623373 0.82 TDP1 (0.46) TDP1L3MBTL1ATMALDH1A1KMT2A
SCHEMBL27790714 0.75 TDP1 (0.46) TDP1L3MBTL1ATMALDH1A1KMT2A
SCHEMBL27775886 0.74 TDP1 (0.49) TDP1L3MBTL1ATMALDH1A1KMT2A
SCHEMBL11212298 0.74 TDP1 (0.61) TDP1L3MBTL1ATMALDH1A1KMT2A
SCHEMBL7194185 0.74 TDP1 (0.61) TDP1L3MBTL1ATMALDH1A1KMT2A
Phenyl Dimethylcarbamate SCHEMBL491227 0.74 RAB9A (0.78) TDP1L3MBTL1ATMALDH1A1KMT2A
SCHEMBL2783232 0.73 ACHE (0.46) TDP1L3MBTL1ATMALDH1A1KMT2A
SCHEMBL12786094 0.72 TDP1 (0.59) TDP1L3MBTL1ATMALDH1A1KMT2A
SCHEMBL27736864 0.72 TDP1 (0.46) TDP1L3MBTL1ATMALDH1A1KMT2A
SCHEMBL9267838 0.71 LMNA (0.59) ATMALDH1A1KMT2ARAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TDP1 4666/4885L3MBTL1 1931/4885ATM 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.